Ingredient or product comparison
Subcutaneous vs Topical: Dosing Protocols and Trade-offs
Subcutaneous injection protocols in published trials typically use 1–3mg GHK-Cu daily, administered in a single dose. A Phase II study evaluating GHK-Cu for photoaged skin used 2mg daily for 12 weeks and demonstrated statistically significant improvements in s
This source-based comparison does not add ratings or recommend a winner.
- Subcutaneous injection protocols in published trials typically use 1–3mg GHK-Cu daily, administered in a single dose. A Phase II study evaluating GHK-Cu for photoaged skin used 2mg daily for 12 weeks and demonstrated statistically significant improvements in skin elasticity (measured via cutometry) and collagen density (confirmed through dermal biopsy). The primary advantage of injectable delivery is precision. You know exactly how much peptide reached systemic circulation. The primary disadvantage is technical: subcutaneous injection requires sterile technique, proper reconstitution of lyophilized powder with bacteriostatic water, and refrigerated storage of the reconstituted solution at 2–8°C.
- Topical formulations sidestep injection requirements but introduce formulation complexity. GHK-Cu is hydrophilic and poorly lipophilic, meaning it doesn't passively cross the lipid-rich stratum corneum. Effective topical delivery requires either lipid encapsulation (liposomes, niosomes, solid lipid nanoparticles) or penetration enhancers like dimethyl sulfoxide (DMSO) or propylene glycol. Concentrations range widely: clinical studies have tested formulations from 0.05% (preventative maintenance) to 2% (intensive collagen remodeling). A 2022 study in Skin Pharmacology and Physiology compared 0.5%, 1%, and 2% GHK-Cu creams applied twice daily. The 2% formulation produced the largest increase in procollagen I gene expression, but the 1% formulation wasn't far behind and caused significantly less erythema.
- Microneedling before topical application is the variable that most dramatically shifts bioavailability. Creating microchannels 0.5–1.5mm deep temporarily disrupts the stratum corneum barrier, allowing peptides to reach the papillary dermis where fibroblasts reside. Studies combining 0.5mm microneedling with 1% GHK-Cu serum showed collagen synthesis markers comparable to 2–3mg injectable protocols. But microneedling introduces controlled micro-injury that itself stimulates wound-healing pathways, making it difficult to isolate GHK-Cu's independent contribution.